Grace Therapeutics (GRCE) Current Leases (2020 - 2023)

Grace Therapeutics has disclosed Current Leases across 4 years of filings, most recently posting $24000.0 for Q4 2023.

• In Q4 2023, Current Leases fell 67.12% year-over-year to $24000.0; the TTM figure through Dec 2023 stood at $24000.0 (down 67.12% YoY), while the FY2023 annual figure was $75000.0, down 27.88% from the prior year.
• Current Leases came in at $24000.0 for Q4 2023 at Grace Therapeutics, down from $46000.0 in the prior quarter.
• In the past five years, Current Leases ranged from a high of $645000.0 in Q2 2022 to a low of $22000.0 in Q4 2021.
• Average Current Leases over 4 years is $104687.5, with a median of $75500.0 recorded in 2020.
• Year-over-year, Current Leases surged 877.27% in 2022 and plunged 87.6% in 2023.
• Over 4 years, Current Leases stood at $105000.0 in 2020, then plunged by 79.05% to $22000.0 in 2021, then soared by 231.82% to $73000.0 in 2022, then sank by 67.12% to $24000.0 in 2023.
• Per Business Quant data, the three most recent Current Leases figures were $24000.0 in Q4 2023, $46000.0 in Q3 2023, and $80000.0 in Q2 2023.